Study guide

11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention

Key Takeaways Explain This Topic AI

Under the DSCSA, pharmacies deal only with authorized trading partners, keep transaction information and statements for 6 years, and quarantine and investigate suspect products.

When a product is found to be illegitimate, the pharmacy must notify FDA on Form 3911, and its trading partners, within 24 hours.

Enhanced DSCSA requirements applied to dispensers with 26 or more pharmacists and technicians from November 27, 2025; FDA exempts small dispensers until November 27, 2027.

Oregon keeps most pharmacy records 3 years, clinical records 7 years, and immunization and prescribing training records 6 years (OAR 855-104-0055).

Oregon pharmacy records stay on site for 12 months, may then move off site but must be produced within 3 business days, and paper non-controlled prescriptions may be imaged after 120 days.

Last updated: October 2026

Why this matters

Area 4.1 includes distribution records, and Area 4.2 covers recordkeeping "in compliance with legal requirements." Two bodies of law dominate. The federal Drug Supply Chain Security Act (DSCSA) governs product tracing and suspect-product handling. Oregon's universal record-retention rule (OAR 855-104-0055) sets how long and where records are kept.

DSCSA basics for dispensers

The DSCSA (FDCA section 582; 21 U.S.C. 360eee-1) built an electronic, interoperable, package-level tracing system in phases ending with "enhanced drug distribution security."

Concept What a pharmacy (dispenser) must know

Authorized trading partners Buy from and sell to only licensed or registered partners: manufacturers, repackagers, wholesale distributors and dispensers

Product identifier Prescription packages carry a 2D DataMatrix code with the NDC, serial number, lot and expiration date

Transaction information (TI) and transaction statement (TS) Received with each change of ownership and kept 6 years . The separate transaction-history requirement ended with the 2023 enhanced-security transition

Verification When a product is suspected, verify the product identifier with the manufacturer, at least the lot and expiration date (and serial numbers under enhanced security), and respond to verification requests

Suspect product Reason to believe it may be counterfeit, diverted, stolen, intentionally adulterated, subject to fraud or unfit. Quarantine and investigate

Illegitimate product Credible evidence of those conditions. Quarantine, notify FDA (Form FDA 3911) and immediate trading partners within 24 hours , dispose of it properly, and keep records

Exemptions Dispensing to a patient is not a "transaction." Sales between dispensers to meet a specific patient need have limited TI exemptions

Compliance timing

FDA's exemptions ended for dispensers with 26 or more full-time pharmacists and technicians on November 27, 2025 . For small dispensers (25 or fewer), FDA extended its exemption from certain enhanced requirements to November 27, 2027 (FDA notice updated August 2026). Core duties already apply to everyone: authorized trading partners, suspect and illegitimate product handling, and record retention.

Oregon's rules mirror these duties. Pharmacists must quarantine and physically separate "suspect or illegitimate" products (OAR 855-115-0125(5); OAR 855-041-1036(1)(d)) and may acquire drugs only from Oregon-registered outlets.

FDA recalls

Class Meaning Pharmacy response

I Reasonable probability of serious adverse health consequences or death Quarantine immediately. Follow the recall depth, often patient level, and contact affected patients

II Temporary or medically reversible adverse effects, or remote probability of serious harm Quarantine and return or destroy as directed

III Unlikely to cause adverse health consequences Remove from stock as directed

The pharmacy's policies must assign responsibility for drug recalls . Central-fill and remote-processing applications must describe this too.

Oregon record retention (OAR 855-104-0055)

Record Retention

Most records required by ORS 475, ORS 689 and OAR 855: prescriptions, refills, transfers, controlled-substance records, temperature logs, self-inspection forms 3 years

Clinical pharmacy records (CDTM, protocol and formulary prescribing, clinical services) 7 years

Training records for immunization and for protocol or formulary prescribing 6 years , or uploaded to the licensee's eGov record

  • CPE proof 6 years (OAR 855-135-0050)
  • PSE/ephedrine sales log 2 years (ORS 475.230)
  • RDSP surveillance video 6 months (still images 3 years)
  • PPL video 30 days (6 months if an incident is under review)
  • Where records are kept

Registrant records: on site for at least 12 months , available immediately at inspection. After that they may be kept in a secure off-site location and produced within 3 business days (OAR 855-104-0055(2); OAR 855-041-1160(5)).

Records outside a registrant , such as a pharmacist's consulting records, are stored securely by the pharmacist and produced within 3 business days.

Records must be kept longer when federal law requires it (for example, DSCSA's 6 years), when the licensee has notice of a Board investigation , or when the Board asks .

Paper non-controlled prescriptions may be destroyed after 120 days if an exact, legible electronic image exists with the clarifications attached (OAR 855-041-1160(3)). Controlled substance prescriptions must be kept in the original form federal rules require.

Note

Federal DEA rules require only 2 years for controlled-substance records (21 CFR 1304.04). Oregon's 3-year rule (OAR 855-080-0070) governs Oregon pharmacies.

Exam scenario

A pharmacy receives a shipment of an oral oncology drug whose packaging looks altered and whose DataMatrix serial number doesn't match the transaction information. The pharmacist quarantines the product, investigates , and asks the manufacturer to verify the identifier. If it is determined to be illegitimate , the pharmacy notifies FDA (Form 3911) and its trading partners within 24 hours . It keeps the investigation records and the transaction documents ( 6 years under DSCSA, longer than Oregon's 3) and documents the quarantine under OAR 855-115-0125(5).